Roche CEO: breast cancer pill could enter $12 bln market if trials succeed

Roche's (ROG.S) experimental oral drug for breast cancer giredestrant could enter a market worth at least 10 billion Swiss francs ($12 billion) a year if it clears two key trials on early treatment of the disease, the Swiss drugmaker's CEO said.